| Eliza Salvo, OD | |
|
341 W Tudor Rd Ste 101, Anchorage, AK 99503-6639 | |
| (907) 770-6652 | |
| (907) 770-3668 |
| Full Name | Eliza Salvo |
|---|---|
| Gender | Female |
| Speciality | Optometrist |
| Location | 341 W Tudor Rd Ste 101, Anchorage, Alaska |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437468774 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 046.010420 (Illinois) | Primary |
| Provider Name | Makar Eyecare Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1497184840 PECOS PAC ID: 6103056023 Enrollment ID: O20140220000347 |
News Archive
The first few weeks after sperm meets egg still hold many mysteries. Among them: what causes the process to fail, leading to many cases of infertility.
Cancer painfully ends more than 500,000 lives in the United States each year, according to the Centers for Disease Control and Prevention. The scientific crusade against cancer recently achieved a victory under the leadership of University of Missouri Curators' Professor M. Frederick Hawthorne.
On September 23, researchers published online in the journal Nature a study of the molecular biology of breast cancer, using the intrinsic subtypes as defined by the PAM50 gene signature as an organizing framework for analyzing genomic and proteomic aberrations. This landmark study both underscores the emergence of the intrinsic subtypes as a powerful taxonomy of breast cancer in research, and PAM50's role as the gold standard for categorizing breast cancer by subtype.
Dyax Corp. today announced financial results for the fourth quarter and year ended December 31, 2009. Dyax will host a webcast and conference call at 10 a.m. (ET) this morning to review the financial results and corporate progress for the quarter.
Vertex Pharmaceuticals Incorporated today announced interim results from an ongoing Phase 2 study designed to assess the safety and tolerability of 12-week response-guided treatment regimens with its polymerase inhibitor, VX-222, and its protease inhibitor, telaprevir, in combination with pegylated-interferon and ribavirin in people with genotype 1 chronic hepatitis C who were new to treatment.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Eliza Salvo, OD 341 W Tudor Rd Ste 101, Anchorage, AK 99503-6639 Ph: (907) 770-6652 | Eliza Salvo, OD 341 W Tudor Rd Ste 101, Anchorage, AK 99503-6639 Ph: (907) 770-6652 |
News Archive
The first few weeks after sperm meets egg still hold many mysteries. Among them: what causes the process to fail, leading to many cases of infertility.
Cancer painfully ends more than 500,000 lives in the United States each year, according to the Centers for Disease Control and Prevention. The scientific crusade against cancer recently achieved a victory under the leadership of University of Missouri Curators' Professor M. Frederick Hawthorne.
On September 23, researchers published online in the journal Nature a study of the molecular biology of breast cancer, using the intrinsic subtypes as defined by the PAM50 gene signature as an organizing framework for analyzing genomic and proteomic aberrations. This landmark study both underscores the emergence of the intrinsic subtypes as a powerful taxonomy of breast cancer in research, and PAM50's role as the gold standard for categorizing breast cancer by subtype.
Dyax Corp. today announced financial results for the fourth quarter and year ended December 31, 2009. Dyax will host a webcast and conference call at 10 a.m. (ET) this morning to review the financial results and corporate progress for the quarter.
Vertex Pharmaceuticals Incorporated today announced interim results from an ongoing Phase 2 study designed to assess the safety and tolerability of 12-week response-guided treatment regimens with its polymerase inhibitor, VX-222, and its protease inhibitor, telaprevir, in combination with pegylated-interferon and ribavirin in people with genotype 1 chronic hepatitis C who were new to treatment.
› Verified 6 days ago
Dr. Gary Michael Kjome, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1000 E Dimond Blvd Ste 101, Anchorage, AK 99515 Phone: 907-349-6932 Fax: 907-349-6347 | |
Marko J Hrgovic, OD Optometrist Medicare: Medicare Enrolled Practice Location: 4125 Debarr Rd, Anchorage, AK 99508 Phone: 907-269-9542 Fax: 907-269-9541 | |
Dr. Patrick Reber, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1345 W 9th Ave, Anchorage, AK 99501 Phone: 907-272-2557 Fax: 907-274-4932 | |
Makar Eyecare Optometrist Medicare: Not Enrolled in Medicare Practice Location: 4411 Business Park Blvd, Bldg. M Ste 10, Anchorage, AK 99503 Phone: 907-770-6652 Fax: 907-770-3668 | |
North Star Optical, Llc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 5710 Denali St, Anchorage, AK 99518 Phone: 907-444-8854 Fax: 888-612-1315 | |
Victoria Ann Blower, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 207 E Northern Lights Blvd, Ste 101, Anchorage, AK 99503 Phone: 907-272-9800 Fax: 907-277-1398 | |
Dimond Vision Clinic Optometrist Medicare: Medicare Enrolled Practice Location: 1000 E Dimond Blvd Ste 101, Anchorage, AK 99515 Phone: 907-349-6932 Fax: 907-349-6347 |